Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

Fig. 4

Association of PD-L1 expression with survival in triple-negative breast cancer (TNBC) patients. a Kaplan-Meier curves of overall survival between tumors with positive and negative PD-L1 expression by IC in the TNBC subgroup with NACT. b Kaplan-Meier curves of distant metastasis-free survival between tumors with positive and negative PD-L1 expression by IC in the TNBC subgroup with NACT. c Kaplan-Meier curves of distant metastasis-free survival between tumors with positive and negative PD-L1 expression by TC in the TNBC group without NACT and with higher stromal tumor-infiltrating lymphocyte (sTIL) level (≥ 10%). d Kaplan-Meier curves of distant metastasis-free survival between tumors with positive and negative PD-L1 expression by IC in the TNBC group with NACT and higher sTIL level (≥ 10%)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us